Welcome! This is the NEW free version of the SciBITES Pharma News Engine from SciBite. By using this site you to accept our Terms & Conditions which the use of cookies to enhance your user experience.


Here is the latest news for your query in chronological order, most recent articles at the top. Use the options on the right to filter and customise this news feed.

  Todays Pfizer (Tag) Articles ...

Improving Maternal Representations in High-Risk Mothers: A Randomized, Controlled Trial of the Mom Power Parenting Intervention.
Medline, Child psychiatry and human development, 24-Sep-2017
A Phase 3b/4,Multi-center, Double-blind, Randomized, Parallel Group Study Of Tofacitinib (Cp-690,550) In Subjects With Ulcerative Colitis In Stable Remission
ClinicalTrials.gov, , 24-Sep-2017
Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay.
Medline, PloS one [12] e0184843, 23-Sep-2017
TIGECYCLINE COMPOSITIONS AND METHODS OF PREPARATION
US/WO/EU Patents, , 23-Sep-2017
METHODS OF TREATING CANCERS WITH THERAPEUTIC NANOPARTICLES
US/WO/EU Patents, , 23-Sep-2017
Your Daily Pharma Scoop: VanEck Vectors Biotech ETF, Esperion's Growth Potential, Pfizer's EU Approval
https://seekingalpha.com, , 22-Sep-2017
FiercePharmaAsia—Big Pharma’s performance, Fosun’s revised Gland buy, Arcus-Taiho cancer deal
http://www.fiercepharma.com, , 22-Sep-2017
Merck, Pfizer get EC approval for skin cancer drug Bavencio
http://regulatoryaffairs.pharmaceutical-business-review.com, , 22-Sep-2017
Phase 3 flop puts Versartis on life support
http://www.fiercebiotech.com, , 22-Sep-2017
Merck, Pfizer cue up first EU launches for PD-L1 drug Bavencio
http://www.pmlive.com, , 22-Sep-2017
First immunotherapy for rare and aggressive skin cancer in the European Union approved
http://www.bionity.com, , 22-Sep-2017
Industry Perspective on Contemporary Protein Binding Methodologies: Considerations for Regulatory Drug-Drug Interaction and Related Guidelines on Highly Bound Drugs.
Medline, Journal of pharmaceutical sciences, 22-Sep-2017
Elastomer Change Out - Justification for minimizing the removal of elastomers in order to prevent cross contamination in a multiproduct facility.
Medline, PDA journal of pharmaceutical science and technology, 22-Sep-2017
Pfizer's fast-growing Ibrance romps toward an early $5B payoff: analyst
http://www.fiercepharma.com, , 21-Sep-2017
Pfizer hits a snag in bid to jump-start Sutent's flagging kidney cancer sales
http://www.fiercepharma.com, , 21-Sep-2017

  This Weeks Pfizer (Tag) Articles ...

Pfizer Goes to Court to Allow Competition for Biologics and Expand Options for Patients
http://www.biomedreports.com, , 21-Sep-2017
Prevalence and correlates of sleep-related problems in adults receiving medical cannabis for chronic pain.
Medline, Drug and alcohol dependence [180] 227-233, 21-Sep-2017
Effect of Water on the Chemical Stability of Amorphous Pharmaceuticals: 2. Deamidation of peptides and proteins.
Medline, Journal of pharmaceutical sciences, 21-Sep-2017
Diagnosis and treatment of attention deficit hyperactivity disorder.
Medline, The Nurse practitioner [42] 48-54, 21-Sep-2017
Comparison of ZFNs versus CRISPR specific nucleases for genome edition of the Wiskott-Aldrich Syndrome locus.
Medline, Human gene therapy, 21-Sep-2017
Showing Records 0 ... 20  


SciBite
The Language Of Science

SciBite provides text-analytics and data intelligence software for drug discovery, clinical and competitor intelligence and much more for pharma, healthcare and life sciences.

This is a Limited, Free Service only touching the surface of how SciBite's tools transform biomedical text, literature, patents, internal documents and news into a rich intelligence network. If you'd like to know more, contact us to see how our tools can transform your work today!

Topic Activity & Tools

Get Daily Alerts!

Click For Email & RSS Alerts

About/Links

Name: Pfizer (Tag)
Type: Company

Filters

Source:


Must Mention A:


In Context:


Insights

Show Most Frequent


Optional, Only Include Source:


Tools

[Not available (Why?)]